These vaccines utilize tumor‐specific antigens (referred to as protein fragments or peptides), such as PSA, PAP, and PSMA in PCa, to trigger the immune system, promoting the production of targeted antibodies or cytotoxic T lymphocytes (also known as killer T cells) for the destruction of tumor cells bearing these specific antigens. The gene discussed is FOLH1; the disease is neoplasm.